Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 12—December 2024
Research

Human Circovirus in Patients with Hepatitis, Hong Kong

Shusheng Wu1, Cyril Chik-Yan Yip1, Jianwen Situ1, Zhiyu Li, Stanley Siu-Fung Ho, Jianpiao Cai, Jane Hau-Ching Poon, Nicholas Foo-Siong Chew, Jonathan Daniel Ip, Tom Wai-Hin Chung, Kelvin Hei-Yeung Chiu, Anna Jinxia Zhang, Estie Hon-Kiu Shun, James Yiu-Hung Tsoi, Jade Lee-Lee Teng, David Christopher Lung, Kelvin Kai-Wang To, Vincent Chi-Chung Cheng, Irene Oi-Lin Ng, Kwok-Yung Yuen, and Siddharth SridharComments to Author 
Author affiliation: The University of Hong Kong, Hong Kong, China (S. Wu, C.C.-Y. Yip, J. Situ, Z. Li, S.S.-F. Ho, J. Cai, J.H.-C. Poon, N.F.-S. Chew, J.D. Ip, A.J. Zhang, J.Y.-H. Tsoi, J.L.-L. Teng, K.K.-W. To, V.C.-C. Cheng, I.O.-L. Ng, K.-Y. Yuen, S. Sridhar); Queen Mary Hospital, Hong Kong (T.W.-H. Chung, K.H.-Y. Chiu, V.C.-C. Cheng); Queen Elizabeth Hospital, Hong Kong (D.C. Lung); Hong Kong Children's Hospital, Hong Kong (D.C. Lung); Centre for Virology, Vaccinology and Therapeutics, Hong Kong (E.H.-K. Shun, K.K.-W. To, K.Y. Yuen)

Main Article

Table 2

Clinical and demographic characteristics of patients with human circovirus infection, Hong Kong*

Patient no. 1 2 3 4 5 6 7 8
Age
 15
 59
 39
 53
 67
 75
 40
 42
Sex
 M
 M
 F
 F
 M
 M
 M
 F
Immunosuppressive condition
 Neuroblastoma
 None
 None
 Kidney graft†
 Liver graft†
 None
 None
 Liver graft†
Organs / blood products
 Y
 N
 N
 Y
 Y
 N
 N
 Y
Peak ALT, U/L
 672
 413
 109
 96
 532
 469
 401
 983
Peak ALP, U/L
 2288
 139
 174
 928
 601
 274
 484
 168
R factor
 0.6
 4.7
 1.6
 0.3
 1.4
 3.2
 1.6
 15.2
Peak bilirubin, µmol/L
 91
 9
 23
 44
 301
 28
 281
 52
Duration of hepatitis
 Chronic
 Acute
 Acute
 Acute
 Acute, relapse
 Acute
 Acute
 Acute
Outcome
 Death
 Survived
 Death
 Survived
 Death
 Survived
 Survived
 Survived
Clinician diagnosis
 NIC
 NIC
 NIC
 NIC
 Chronic rejection
 COVID-19
 Cholangitis
 Anastomotic stricture
Expert 1 diagnosis
 Drug-induced hepatitis
 NIC
 Ischemic hepatitis
 Drug-induced cholestasis
 NIC
 COVID-19
 Cholangitis
 Rejection
Expert 2 diagnosis NIC NIC NIC NIC NIC Gallstone Cholangitis Anastomotic stricture

*ALP, alkaline phosphatase; ALT, alanine aminotransferase; NIC, no identifiable single cause for hepatitis. †Time from transplantation to hepatitis: patient 4, 1 month; patient 5, 15 years; patient 8, 22 months.

Main Article

1These authors contributed equally to this article.

Page created: October 04, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external